Takanori Taogoshi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Takanori Taogoshi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Hiroaki Matsuo
Department of Pharmaceutical Services, Hiroshima University Hospital, Hiroshima, Japan
2 shared publications - Genki Kidoguchi
Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital , Hiroshima
1 shared publication - Hiroki Kobayashi
Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital , Hiroshima
1 shared publication Kana Miyamoto
Department of Pharmaceutical Services, Hiroshima University Hospital , Hiroshima
1 shared publication- Kazutaka Oda
Department of Pharmacy Kumamoto University Hospital Kumamoto Japan
1 shared publication - Kei Araki
Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, 1-2-3 Kasumi Minami, Hiroshima, 734-8551, Japan
1 shared publication
Latest Publications
- 4 August 2026
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 15 (8)
Factors Affecting the Initial Serum Concentration of Teicoplanin in Pediatric Patients: A Single-Center Retrospective Analysis
Background: The glycopeptide antibiotic teicoplanin (TEIC) is used to treat infections caused by methicillin-resistant Staphylococcus aureus and other gram-positive bacteria. Because higher target trough concentrations are now recommended, higher loading dose (LD) regimens have been proposed. However, the factors affecting trough concentration (Ctrough) levels and the safety of high-dose regimens remain unclear. This study aimed to investigate the factors that should be considered in the LD regimen of TEIC in pediatric patients and assess the safety of a higher LD. Methods: We enrolled pediatric patients aged 1-14 years with available TEIC concentrations measured between August 2013 and December 2024. Factors affecting the initial Ctrough and the initial Ctrough divided by LD per kilogram of body weight (C/D ratio) were investigated. Safety assessment included serious adverse reactions at the time of initial Ctrough measurement. Results: In total, 108 patients were enrolled in this study. Of 108 enrolled patients, 64 patients were measured initial Ctrough on day 4. Fifty-four patients received higher LD (average 54.2 mg/kg/3 days) than the standard regimen, with 33 patients (52%) not achieving an initial Ctrough of 15 μg/mL. Linear regression analysis showed that the initial Ctrough was associated with age (P = .008), estimated glomerular filtration rate (eGFR; P < .001), and serum albumin level (P = .017). The C/D ratio on day 4 was associated with eGFR (P < .001) and the presence or absence of febrile neutropenia (FN) (P = .046). Further analysis restricted to patients with FN indicated that bone marrow transplantation (BMT) (P = .046) affected the C/D ratio. Serious adverse reactions occurred in 5 cases. Conclusions: Clinical conditions, such as FN and BMT, which cause an increase in eGFR, may affect the initial Ctrough in pediatric patients. Moreover, a higher LD was well-tolerated. When determining the LD, clinical conditions must be considered.
- 4 August 2026
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 15 (8)
Factors Affecting the Initial Serum Concentration of Teicoplanin in Pediatric Patients: A Single-Center Retrospective Analysis
Background: The glycopeptide antibiotic teicoplanin (TEIC) is used to treat infections caused by methicillin-resistant Staphylococcus aureus and other gram-positive bacteria. Because higher target trough concentrations are now recommended, higher loading dose (LD) regimens have been proposed. However, the factors affecting trough concentration (Ctrough) levels and the safety of high-dose regimens remain unclear. This study aimed to investigate the factors that should be considered in the LD regimen of TEIC in pediatric patients and assess the safety of a higher LD. Methods: We enrolled pediatric patients aged 1-14 years with available TEIC concentrations measured between August 2013 and December 2024. Factors affecting the initial Ctrough and the initial Ctrough divided by LD per kilogram of body weight (C/D ratio) were investigated. Safety assessment included serious adverse reactions at the time of initial Ctrough measurement. Results: In total, 108 patients were enrolled in this study. Of 108 enrolled patients, 64 patients were measured initial Ctrough on day 4. Fifty-four patients received higher LD (average 54.2 mg/kg/3 days) than the standard regimen, with 33 patients (52%) not achieving an initial Ctrough of 15 μg/mL. Linear regression analysis showed that the initial Ctrough was associated with age (P = .008), estimated glomerular filtration rate (eGFR; P < .001), and serum albumin level (P = .017). The C/D ratio on day 4 was associated with eGFR (P < .001) and the presence or absence of febrile neutropenia (FN) (P = .046). Further analysis restricted to patients with FN indicated that bone marrow transplantation (BMT) (P = .046) affected the C/D ratio. Serious adverse reactions occurred in 5 cases. Conclusions: Clinical conditions, such as FN and BMT, which cause an increase in eGFR, may affect the initial Ctrough in pediatric patients. Moreover, a higher LD was well-tolerated. When determining the LD, clinical conditions must be considered.
- Open Access
- 6 June 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (7) , 3957-3965
Effect of different folic acid doses on methotrexate-related toxicity and its association with erythrocyte methotrexate-polyglutamates in patients with rheumatic diseases: a single-center exploratory randomized controlled trial
Introduction: Folic acid is routinely co-administered with methotrexate (MTX) to reduce toxicity; however, the optimal dose remains unclear. This study investigated whether increasing the weekly folic acid dose from 5 to 10 mg reduces MTX-related toxicity in patients receiving stable-dose MTX therapy. Methods: In this single-center, open-label, randomized controlled trial, 44 patients with rheumatic diseases on stable-dose MTX either received 10 mg (ARM-1) or 5 mg (ARM-2) of folic acid per week for 12 weeks. Liver damage, other MTX-related toxicities, and erythrocyte MTX-polyglutamate (MTX-PG) concentrations were compared between groups using logistic regression analysis or analysis of covariance. Japan Registry of Clinical Trials (number: jRCT1061230085). Results: Forty-two patients completed the study. The presence of liver damage at Day 84 did not differ significantly between the two groups (OR 0.41, 95% CI, 0.01–5.75, p = 0.506). Adjusted mean differences in aspartate transaminase and alanine transaminase at Day 84 between the groups were − 0.33 U/L (95% CI, − 2.68 to 2.02; p = 0.779) and − 0.44 U/L (95% CI, − 5.39 to 4.51; p = 0.859). Comparison of outcomes between groups at Day 84 showed no significant differences in any outcomes, except for fatigue severity (adjusted mean difference, − 0.87; 95% CI, − 1.71 to − 0.04; p = 0.041). Baseline fatigue was associated with baseline MTX-PG2 or MTX-PG1-2 concentrations (OR, 1.06; p = 0.049 or OR, 1.03; p = 0.040, respectively). Conclusions: Increasing folic acid dose to 10 mg/week showed little effect on reducing MTX-related toxicity, although it may improve fatigue in selected patients. Key Points • Increasing the weekly folic acid dose from 5 mg to 10 mg showed no additional benefit in reducing methotrexate-related toxicity in patients on stable-dose MTX. • Higher-dose folic acid was associated with improved fatigue severity, indicating a potential therapeutic option for patients who develop fatigue.
- 6 June 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (7) , 3957-3965
Open AccessEffect of different folic acid doses on methotrexate-related toxicity and its association with erythrocyte methotrexate-polyglutamates in patients with rheumatic diseases: a single-center exploratory randomized controlled trial
Introduction: Folic acid is routinely co-administered with methotrexate (MTX) to reduce toxicity; however, the optimal dose remains unclear. This study investigated whether increasing the weekly folic acid dose from 5 to 10 mg reduces MTX-related toxicity in patients receiving stable-dose MTX therapy. Methods: In this single-center, open-label, randomized controlled trial, 44 patients with rheumatic diseases on stable-dose MTX either received 10 mg (ARM-1) or 5 mg (ARM-2) of folic acid per week for 12 weeks. Liver damage, other MTX-related toxicities, and erythrocyte MTX-polyglutamate (MTX-PG) concentrations were compared between groups using logistic regression analysis or analysis of covariance. Japan Registry of Clinical Trials (number: jRCT1061230085). Results: Forty-two patients completed the study. The presence of liver damage at Day 84 did not differ significantly between the two groups (OR 0.41, 95% CI, 0.01–5.75, p = 0.506). Adjusted mean differences in aspartate transaminase and alanine transaminase at Day 84 between the groups were − 0.33 U/L (95% CI, − 2.68 to 2.02; p = 0.779) and − 0.44 U/L (95% CI, − 5.39 to 4.51; p = 0.859). Comparison of outcomes between groups at Day 84 showed no significant differences in any outcomes, except for fatigue severity (adjusted mean difference, − 0.87; 95% CI, − 1.71 to − 0.04; p = 0.041). Baseline fatigue was associated with baseline MTX-PG2 or MTX-PG1-2 concentrations (OR, 1.06; p = 0.049 or OR, 1.03; p = 0.040, respectively). Conclusions: Increasing folic acid dose to 10 mg/week showed little effect on reducing MTX-related toxicity, although it may improve fatigue in selected patients. Key Points • Increasing the weekly folic acid dose from 5 mg to 10 mg showed no additional benefit in reducing methotrexate-related toxicity in patients on stable-dose MTX. • Higher-dose folic acid was associated with improved fatigue severity, indicating a potential therapeutic option for patients who develop fatigue.